Privium Fund Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Privium Fund Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.29M	Hold	90,110	–	–	0.25%	37
2026 Q2	$1.2M	Sell	90,110 -80,146	-47%	-$781K	0.22%	43
2026 Q1	$1.59M	Sell	170,256 -39,744	-19%	-$346K	0.33%	37
2025 Q4	$1.58M	Buy	210,000 +12,542	+6%	+$127K	0.29%	36
2025 Q3	$1.72M	Hold	197,458	–	–	0.31%	33
2025 Q2	$819K	Buy	197,458 +66,458	+51%	+$234K	0.18%	37
2025 Q1	$423K	Buy	131,000 +10,000	+8%	+$47.1K	0.11%	45
2024 Q4	$674K	Buy	121,000 +22,500	+23%	+$177K	0.15%	39
2024 Q3	$1.06M	Buy	98,500 +58,500	+146%	+$971K	0.26%	34
2024 Q2	$823K	Buy	40,000 +9,000	+29%	+$226K	0.21%	48
2024 Q1	$988K	Sell	31,000 -2,680	-8%	-$68.4K	0.26%	43
2023 Q4	$716K	Hold	33,680	–	–	0.2%	51
2023 Q3	$429K	Buy	+33,680	New	+$563K	0.13%	61

Other funds holding FDMT

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Privium Fund Management's FDMT Position: Q3 2026 in Review

Privium Fund Management held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 90,110 shares worth $1.29M. The position accounts for 0.25% of the portfolio, ranked #37.

Privium Fund Management first reported a position in FDMT in Q3 2023 and has held it in 13 quarters since. The position peaked at $1.72M in Q3 2025. 40 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

Privium Fund Management held 90,110 shares of 4D Molecular Therapeutics worth $1.29M as of Q3 2026.
Privium Fund Management left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
4D Molecular Therapeutics made up 0.25% of Privium Fund Management's portfolio in Q3 2026, its #37 holding.
Privium Fund Management first reported a position in 4D Molecular Therapeutics in Q3 2023 and has held it in 13 quarters since.
Privium Fund Management's 4D Molecular Therapeutics position peaked at $1.72M in Q3 2025.
40 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Privium Fund Management's 13F filing for Q3 2026, filed 3 Nov 2026.